KYTX · Kyverna Therapeutics, Inc.
$7.76
+0.12 (+1.57%)
At close · Aug 6
Market Cap
$464.48M
Shares
60.80M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.64
Open$7.84
Day$7.55–7.89
52W$2.80–13.67
Avg vol 30d1.3M
Short int7.8M · 12.9% float · 6.1d
Short vol36%
Last earningsJan 12, 2026
DataFeb 2024–Aug 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−8%
below
Price vs 50-day avg
−6%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
45%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
+1%
trailing
YTD return
−19%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
31 of 112 funds reported for Jun 30 · net +318.6K sh shares · +9 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.91% of float · ▲ +8.7% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 2-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
EPS growth
−9%
Y/Y
Free cash flow
$-153.7M
Balance sheet
$124.1M
net cash
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−8%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
45%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $8 — 200d above 50d
Institutional flow
Accumulating
31 of 112 funds reported for Jun 30 · net +318.6K sh shares · +9 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.91% of float · ▲ +8.7% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
112 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $8 · 45%
52-wk high $14
vs 200-day avg -8%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KYTX
this stock
Kyverna Therapeutics, Inc.
|
$464.48M | -18.7% | — | — | 12.9% |
|
ONC
BeOne Medicines Ltd.
|
$484.13B | +7.8% | +22179.2% | 744.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.89B | +6.9% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.13B | -0.2% | +20.8% | 19.0 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +3.2% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KYTX | +8.1% | -22.9% | +1.2% | +4.7% | -18.7% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | +2.5% | -26.2% | -10.1% | +1.6% | -31.6% |
Key facts
CIK
1994702
CUSIP
501976104
13F (30d)
29 filings
29 filers
Visit website
Investor relations